Gabrail Cancer Research Center

Canton, Ohio 44718

8 studies enrolling now · 16 studies all time

What they study most

ALK-Positive Large B-Cell Lymphoma, Acneiform Eruption Due to Chemical, Advanced Cancer, Advanced Solid Tumor, Breast Cancer, Breast Cancer Metastatic, Breast Neoplasm, Burkitt Lymphoma, CCNE1 Amplification, CRC (Colorectal Cancer), CRC, Colorectal Cancer, Chronic Lymphocytic Leukemia

Studies at this site

• Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. — Recruiting now
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer — Recruiting now
• Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors — Recruiting now
• Study of SGR-1505 in Mature B-Cell Neoplasms — Recruiting now
• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors — Recruiting now
• Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia — Recruiting now
• FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations — Recruiting now
• Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) — Recruiting now
• A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies — Running, not enrolling
• Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) — Completed
• Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors — Running, not enrolling
• CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC — Completed
• EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer — Stopped early
• A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors — Withdrawn before enrolling
• Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck — Completed
• A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients — Withdrawn before enrolling